iCAD

[#ECR2025] One Month Countdown! Who’s excited to meet up in Vienna, Austria for the European Society of Radiology’s ECR Congress? 2025 is an exciting year for Breast AI innovations. We’d love to see you while you’re there, or meet up virtually. Let’s Connect: https://bit.ly/4hc6ozB #ProFoundAI #ProFoundCloud #EarlyDetection #RadiologyAI #BreastAI

One of the biggest challenges in breast cancer screening? Balancing early detection with minimizing unnecessary recalls for patients. AI in radiology isn’t just about snapshots of risk—it’s about tracking patterns over time. In this latest study by Penn Medicine, University of Pennsylvania Health System and iCAD in Radiology: AI shows that changes in AI case scores over multiple screenings could be a game-changer for breast cancer detection. Why does this matter? -> Instead of a single AI score, tracking how scores evolve over time could improve recall decisions and reduce missed cancers. -> AI case scores increase most in true cancer cases, reinforcing confidence in early detection. -> AI-driven insights could enhance workflow efficiency and reduce unnecessary callbacks. This is just the beginning! AI is evolving from a diagnostic tool to a true decision-support partner for radiologists. Looking forward to collaborating with clinicians, researchers, and industry experts to keep pushing the boundaries of AI in healthcare! https://lnkd.in/d3kCzssb #AI #HealthAI #Innovation #BreastCancer #BreastHealth

Today, iCAD pre-announced estimated Q4 2024 revenue and management participation in the BTIG at Snowbird: 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.   Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2024 to be between approximately $5.1 and approximately $5.3 million. Total Annual Recurring Revenue (T-ARR) was approximately $9.8 million, up 11% year-over-year. In the fourth quarter of 2024, the Company closed 106 deals, 19 of which were cloud deals with both new and established customers.   iCAD also announced it will participate in the BTIG at Snowbird: 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025, in Snowbird, Utah. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD will participate in one-on-one meetings with investors at the event.    Read more: bit.ly/3Wuoqof

#ECR2025 is approaching! iCAD continues to lead the way with wide-ranging AI solutions, cloud-enabled connectivity, and next generation algorithms that are transforming patient care and breast health for the future. Be a part of what's next and book a meeting with our team ! #BreastAI #Healthcare #ECR2025

It’s been over 40 years of innovation. The technology has changed, but our mission of saving lives through medical imaging has stayed the same. Founded in 1984 in Hudson, NH (near Nashua), iCAD began as R.H. Research, later renamed Howtek, Inc. The company initially focused on printing and image scanning technologies, including a color 2D printer using thermoplastic ink and digitizing systems that converted hard-copy images into digital formats for industries such as graphic arts, photo finishing, and medical imaging. In the early 2000s, following strategic acquisitions of Intelligent Systems Software, Inc. (ISSI), Qualia Computing, Inc., and its subsidiary CADx Systems, Inc., Howtek rebranded as iCAD. The acquisitions brought FDA-cleared Computer-Aided Detection (CAD) technologies for breast cancer into its portfolio. Mammographic film scanning and pre-AI CAD were leveraged in this innovative strategic portfolio to assist radiologists in detecting breast cancer more effectively. With its renewed focus and expanded capabilities, iCAD established itself as a leader in breast cancer imaging solutions, paving the way for continued advancements in deep learning AI solutions. In 2016, iCAD released an industry-first 3D AI mammography solution for DBT which received FDA approval in 2017. In 2021, iCAD released an industry first, 3D AI Risk* solution for DBT. In late 2024, iCAD received FDA clearance of ProFound Detection v4, the next generation of iCAD’s AI detection solutions. Discover the next generation of ProFound Detection: https://bit.ly/42scBTG #ProFoundAI #EarlyDetection #RadiologyAI #BreastAI

[#CaseStudy] This 67-year-old woman with scattered fibroglandular densities had a history of benign needle aspiration, right breast, and no family history of breast cancer. First DBT Screening: BI-RADS 2 Screening DBT with no newly developed dominant mass, suspicious microcalcification cluster, or architectural distortion is appreciated. Benign breast calcifications noted. 🌟 She returned for a 14-month Follow-up DBT Screening, and that scan was processed using both the 3rd and 4th generation of ProFound AI Detection: 🔷 ProFound AI Detection V3 marked 3 vascular calcs. Current: Case Score 45 | Lesion Scores 34, 21 and 16. All FPs on vascular calcs. 🔷 ProFound Detection V4 did not mark any vascular calcs. Current: Case Score 18 | No FPs. 🎯 ProFound Detection v4 is more precise reading screening DBT, which saves the radiologist time and effort in reading mammograms. Learn More: https://bit.ly/40hhyfg #ProFoundAI #BreastAI #RadiologyAI

New Research Publication - We are proud to share that iCAD and our research collaborators from the University of Pennsylvania have had their latest manuscript accepted in the Radiology Artificial Intelligence Journal! Title: Evaluating the Impact of Changes in AI-derived Case Scores over Time on Digital Breast Tomosynthesis Screening Outcomes. Key Insight: Tracking changes in DBT-AI case scores over time can help radiologists make more informed recall decisions, leading to better outcomes and improved screening performance. At iCAD, we are dedicated to advancing breast health through cutting-edge AI-driven solutions. This study highlights the potential value of leveraging longitudinal data to empower radiologists with actionable insights and optimize patient care. Stay tuned for more updates on how iCAD's innovations are transforming breast health! Read more: https://bit.ly/4jwCgAL 👉 We’d love to hear your thoughts on this breakthrough—share them in the comments below! #WhatsNextInAI #BreastAI #ProFoundAI #BreastCancerDetection #RadiologyAI #EarlyDetection

💡 ProFound Detection v4 incorporates prior mammograms into its analysis, delivering greater accuracy and precision by drawing from a fuller picture of each patient’s breast health over time. Experience the impact of Breast AI that empowers #radiologists and supports earlier, more accurate cancer detection. Discover More: https://bit.ly/3DVXKGM #WhatsNextInAI #BreastAI #ProFoundAI #BreastCancerDetection #RadiologyAI #EarlyDetection

🚀☁️ Speed. Scalability. Security. In our first 200,000 mammography cases processed in in ProFound Cloud, customers are seeing an average turnaround time improvement of over 60% faster compared to many traditional on-premises deployment solutions. You don’t have to change for us to realize the key clinical and operational benefits of the ProFound AI Breast Health Suite. Discover More: https://bit.ly/3DX9KaW #ProFoundCloud #ProFoundAI #BreastAI #RadiologyAI

Today, we reflect on the power of these words and their enduring relevance. Access to quality care should never depend on where someone lives, their income, or the color of their skin. At iCAD, we are committed to breaking down barriers in breast cancer detection with innovative AI solutions, ensuring that every patient, everywhere, has the chance to receive the care they deserve. Let’s honor Dr. King's legacy by taking steps—big and small—toward equality in healthcare. Together, we can make a difference. 💙 #MLKDay Learn More about Breast Cancer Health Disparities: https://bit.ly/40xIf0v #InclusionMatters #UnityInDiversity